Elicera Therapeutics completes Phase I CARMA trial of ELC-301, posts 67% complete metabolic response rate

By Public Technologies
  • Elicera Therapeutics reported completed dose-escalation in the CARMA Phase I/IIa trial of ELC-301 in relapsed or refractory B-cell lymphoma.
  • Results have already been presented, showing most patients responded, with many reaching no detectable active disease at best response.
  • Responses appeared durable in several patients, supporting continued development despite prior treatment failures in the enrolled population.
  • Safety supported further testing, with no dose-limiting toxicities reported across the evaluated dose cohorts.
  • Recruitment is expected to start in Q4 2026 for the Phase IIa expansion, which will further assess dosing and early efficacy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicera Therapeutics AB published the original content used to generate this news brief via Cision (Ref. ID: 202610120705BITN____UKPR__EN_20261012-BIT-2244-0) on October 12, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.